X

Trial Profile

Efficacy and safety of oral semaglutide 50 mg once daily in subjects with overweight or obesity

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semaglutide (Primary)
Indications Obesity
Focus Registrational; Therapeutic Use
Acronyms OASIS 1
Sponsors Novo Nordisk

Most Recent Events

29 Jun 2023 Results assessing the efficacy and safety of oral semaglutide 50 mg versus placebo for the treatment of overweight or obesity, published in the Lancet
25 Jun 2023 Results presented in the American Diabetes Association media release.
25 Jun 2023 According to a Boehringer Ingelheim media release, data from this trial were presented at the 2023 American Diabetes Association's 83rd Scientific Sessions.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com